Supernus Pharmaceuticals (SUPN) reported $192.1 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 9.3%. EPS of $1.01 for the same period compares to $1.06 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $182.06 million, representing a surprise of +5.52%. The company delivered an EPS surprise of +23.17%, with the consensus EPS estimate being $0.82.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product sales- Trokendi XR: $10 million compared to the $7.59 million average estimate based on two analysts. The reported number represents a change of -34.6% year over year.
- Revenues- Net product sales- Oxtellar XR: $12.1 million compared to the $6.27 million average estimate based on two analysts. The reported number represents a change of -59.4% year over year.
- Revenues- Net product sales: $168.54 million versus the two-analyst average estimate of $176.8 million. The reported number represents a year-over-year change of -1%.
- Revenues- Net product sales- GOCOVRI: $40.8 million compared to the $37.68 million average estimate based on two analysts. The reported number represents a change of +14.6% year over year.
- Revenues- Net product sales- Qelbree: $81.4 million compared to the $79.95 million average estimate based on two analysts. The reported number represents a change of +30.5% year over year.
View all Key Company Metrics for Supernus here>>>
Shares of Supernus have returned +15.3% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
